Compare Adaptive Biotechnologies Corp (ADPT) vs Aspen Aerogels Inc (ASPN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Aspen Aerogels Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Aspen Aerogels Inc trades at $5.11 (market cap $425.99M). The key difference: Adaptive Biotechnologies Corp is far larger — about 7.8× Aspen Aerogels Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Aspen Aerogels Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | ASPN | |
|---|---|---|
Market Cap | $3.33B | $425.99M |
Sector | Health | Technology |
52-Week High | $22.37 | $8.82 |
52-Week Low | $10.24 | $2.57 |
Enterprise Value | $3.19B | $380.94M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
ASPN trades at $5.47, down 1.97% today, with a bearish technical signal despite bullish moving averages. The company reported a Q1 2026 net loss of $0.28 per share, missing estimates, but revenue beat expectations. Recent news includes a 2025 Supplier of the Year award from General Motors and the staged restart of its East Providence facility after an incident. Cash flow improved in 2026 projections, with net cash flow narrowing to -$17 million from -$63 million in 2025.
Outlook remains challenging with persistent losses and negative margins, but analyst sentiment is strongly bullish (83% buy ratings). Key risks include execution on facility restarts, EV demand volatility, and cash burn. The stock's investment case hinges on operational turnaround and revenue growth acceleration amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Aspen Aerogels Inc
Aspen Aerogels is an aerogel technology company that designs high-performance insulation. Its products are used in energy infrastructure and electric vehicles to provide thermal management and fire protection.
Read more on ASPN →
